Zacks Investment Research Upgrades Autolus Therapeutics (NASDAQ:AUTL) to “Buy”

Autolus Therapeutics (NASDAQ:AUTL – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday, Zacks.com reports. The brokerage currently has a $3.00 price target on the stock. Zacks Investment Research‘s target price would indicate a potential upside of 7.14% from the stock’s current price.

According to Zacks, “Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. The company’s pipeline of product candidate involved in development for the treatment of haematological malignancies and solid tumours. Autolus Therapeutics plc is based in London, United Kingdom. “

Separately, William Blair reaffirmed an “outperform” rating on shares of Autolus Therapeutics in a report on Thursday, March 10th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $11.00.

NASDAQ:AUTL traded up $0.07 during mid-day trading on Thursday, reaching $2.80. 140,037 shares of the stock were exchanged, compared to its average volume of 341,612. The business has a fifty day moving average price of $3.70 and a 200 day moving average price of $4.60. The firm has a market capitalization of $254.54 million, a PE ratio of -1.51 and a beta of 1.60. Autolus Therapeutics has a 1-year low of $2.20 and a 1-year high of $8.23.

Autolus Therapeutics (NASDAQ:AUTL – Get Rating) last released its earnings results on Thursday, May 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.10. The firm had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.26 million. Autolus Therapeutics had a negative return on equity of 52.00% and a negative net margin of 6,551.06%. During the same period in the previous year, the company earned ($0.53) earnings per share. As a group, research analysts expect that Autolus Therapeutics will post -1.78 earnings per share for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Syncona Portfolio Ltd purchased a new position in Autolus Therapeutics in the 4th quarter worth about $38,130,000. Nantahala Capital Management LLC increased its stake in Autolus Therapeutics by 6.6% in the 1st quarter. Nantahala Capital Management LLC now owns 4,346,327 shares of the company’s stock worth $18,124,000 after purchasing an additional 268,818 shares in the last quarter. Frazier Management LLC increased its stake in Autolus Therapeutics by 6.1% in the 4th quarter. Frazier Management LLC now owns 3,746,857 shares of the company’s stock worth $19,446,000 after purchasing an additional 216,200 shares in the last quarter. Frazier Life Sciences Management L.P. purchased a new position in Autolus Therapeutics in the 1st quarter worth about $15,624,000. Finally, Pendal Group Ltd grew its stake in Autolus Therapeutics by 2.6% during the 4th quarter. Pendal Group Ltd now owns 1,444,802 shares of the company’s stock valued at $7,499,000 after acquiring an additional 36,485 shares in the last quarter. 61.45% of the stock is currently owned by hedge funds and other institutional investors.

About Autolus Therapeutics (Get Rating)

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma.

Recommended Stories